Head to Head Review: ADB International Group (OTCMKTS:EQUR) vs. Solana (NASDAQ:HSDT)

Solana (NASDAQ:HSDT) and ADB International Group (OTCMKTS:EQUR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Earnings & Valuation

This table compares Solana and ADB International Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02 million	18.78	-$40.89 million	($490.68)	0.00
ADB International Group	N/A	N/A	N/A	N/A	N/A

ADB International Group has lower revenue, but higher earnings than Solana.

Profitability

This table compares Solana and ADB International Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-679.54%	-104.96%	-20.67%
ADB International Group	N/A	N/A	N/A

Institutional & Insider Ownership

18.6% of Solana shares are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Comparatively, 79.6% of ADB International Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Solana and ADB International Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	0	2	0	2.33
ADB International Group	0	0	0	0	0.00

Solana presently has a consensus target price of $3.50, suggesting a potential upside of 69.90%. Given Solana’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Solana is more favorable than ADB International Group.

Summary

Solana beats ADB International Group on 5 of the 9 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About ADB International Group

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The company was incorporated in 1988 and is based in New York, New York.